Drug intelligence / Profile preview

fotemustine + vemurafenib

Development stage: Unknown
Lead developer: Servier
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of fotemustine, a nitrosourea alkylating agent, and vemurafenib, a BRAF inhibitor targeting the BRAF V600E mutation. This combination has been investigated for treating patients with BRAF-mutated metastatic melanoma who have developed resistance to prior BRAF inhibitor monotherapy. Clinical trials have shown that the combination has activity in BRAF-refractory patients with an acceptable safety profile.

Targets

BRAF (B-Raf proto-oncogene, serine/threonine kinase)DNA

Beyond the preview

Go deeper on fotemustine + vemurafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fotemustine + vemurafenib.

Explore the full profile